Immutep Ltd
ASX:IMM

Watchlist Manager
Immutep Ltd Logo
Immutep Ltd
ASX:IMM
Watchlist
Price: 0.46 AUD 10.84% Market Closed
Market Cap: AU$677.1m

Net Margin

-102 220%
Current
Declining
by 57 189.4%
vs 3-y average of -45 030.5%

Net Margin shows how much profit a company keeps from each dollar of sales after all expenses, including taxes and interest. It reflects the company`s overall profitability.

Net Margin
-102 220%
=
Net Income
AU$-61.4m
/
Revenue
AU$60.1k

Net Margin shows how much profit a company keeps from each dollar of sales after all expenses, including taxes and interest. It reflects the company`s overall profitability.

Net Margin
-102 220%
=
Net Income
AU$-61.4m
/
Revenue
AU$60.1k

Peer Comparison

Country Company Market Cap Net
Margin
AU
Immutep Ltd
ASX:IMM
671.8m AUD
Loading...
FR
Pharnext SCA
OTC:PNEXF
6T USD
Loading...
US
Abbvie Inc
NYSE:ABBV
390.3B USD
Loading...
US
Amgen Inc
NASDAQ:AMGN
186.5B USD
Loading...
US
Gilead Sciences Inc
NASDAQ:GILD
168.8B USD
Loading...
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
119.8B USD
Loading...
US
Epizyme Inc
F:EPE
94.1B EUR
Loading...
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
79.9B USD
Loading...
AU
CSL Ltd
ASX:CSL
87B AUD
Loading...
NL
argenx SE
XBRU:ARGX
42.4B EUR
Loading...
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
47.5B USD
Loading...

Market Distribution

Lower than 96% of companies in Australia
Percentile
4th
Based on 4 004 companies
4th percentile
-102 220%
Low
-16 177 900% — -544.7%
Typical Range
-544.7% — 3.1%
High
3.1% — 3 174 540%
Distribution Statistics
Australia
Min -16 177 900%
30th Percentile -544.7%
Median -27.7%
70th Percentile 3.1%
Max 3 174 540%

Immutep Ltd
Glance View

Market Cap
677.1m AUD
Industry
Biotechnology

Immutep Ltd. is a biotechnology company, which engages in the research and development of immunotherapeutic treatments for cancer and autoimmune diseases. The company is headquartered in Sydney, New South Wales. The firm is engaged in the development of LAG-3 immunotherapeutic products for cancer and autoimmune disease. The firm has four product candidates based on the LAG-3 immune control mechanism. Its lead product candidate, eftilagimod alpha (efti or IMP321), is a soluble LAG-3Ig fusion protein, which is in later-stage clinical development for the treatment of cancer. Its second product candidate (IMP761) is in pre-clinical development for the treatment of autoimmune disease. The Company’s two licensed product candidates include Antagonist AB (LAG525) and Depleting AB (GSK‘781). The Company’s operates through its subsidiaries, which includes Immutep USA Inc, PRR Middle East FZ LLC, Immutep GmbH, Immutep Australia Pty Ltd, Immutep IP Pty Ltd and Immutep S.A.S.

IMM Intrinsic Value
0.13 AUD
Overvaluation 71%
Intrinsic Value
Price
What is Net Margin?
Net Margin shows how much profit a company keeps from each dollar of sales after all expenses, including taxes and interest. It reflects the company`s overall profitability.
How is Net Margin calculated?

Net Margin is calculated by dividing the Net Income by the Revenue.

Net Margin
-102 220%
=
Net Income
AU$-61.4m
/
Revenue
AU$60.1k
What is Immutep Ltd's current Net Margin?

The current Net Margin for Immutep Ltd is -102 220%, which is below its 3-year median of -45 030.5%.

How has Net Margin changed over time?

Over the last 3 years, Immutep Ltd’s Net Margin has decreased from -12 661.5% to -102 220%. During this period, it reached a low of -102 220% on Jun 30, 2025 and a high of -12 661.5% on Jun 30, 2022.

Back to Top